Kristian Reich, Peter A Lio, Robert Bissonnette, Andrew F Alexis, Mark G Lebwohl, Andrew E Pink, Kenji Kabashima, Mark Boguniewicz, Roman J Nowicki, Hernan Valdez, Fan Zhang, Marco DiBonaventura, Michael C Cameron, Claire Clibborn
BACKGROUND: Emerging treatments for moderate-to-severe atopic dermatitis (AD) may provide greater and faster improvement in AD signs and symptoms than current therapies. OBJECTIVE: Examine JADE COMPARE (NCT03720470) data using stringent efficacy end points. METHODS: Adults with moderate-to-severe AD were randomly assigned 2:2:2:1 to receive oral abrocitinib 200 or 100 mg once daily, subcutaneous dupilumab 300 mg every 2 weeks (600-mg loading dose), or placebo, with medicated topical therapy for 16 weeks...
September 12, 2022: Journal of Allergy and Clinical Immunology in Practice